Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Silence Therapeutics Plc (SLN.LN)

Silence Therapeutics Plc (SLN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Silence Therapeutics Plc 72 Hammersmith Road London W14 8TH GBR

https://www.silence-therapeutics.com P: 203-457-6900

Description:

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

Key Statistics

Overview:

Market Capitalization, $K 480,348
Shares Outstanding, K 89,785
Annual Sales, $ 25,375 K
Annual Net Income, $ -43,267 K
Last Quarter Sales, $ 2,099 K
Last Quarter Net Income, $ -14,412 K
% of Insider Shareholders 70.46%
% of Institutional Shareholders 2.37%

Growth:

1-Year Return 27.99%
3-Year Return 522.09%
5-Year Return 390.83%

Per-Share Information:

Latest Earnings Date N/A
Earnings Per Share ttm -0.49
Dividend Payout Ratio 0.00%
Most Recent Split 1-50 on 04/30/13

SLN.LN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -221.19%
Return-on-Assets % -42.98%
Profit Margin % -170.51%
Debt/Equity 0.01
Price/Sales 41.14
Price/Book 29.36
Book Value/Share 0.18
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar